Literature DB >> 32470973

Association of serum interleukin-6 and soluble interleukin-2-receptor levels with disease activity status in patients with inflammatory bowel disease: A prospective observational study.

Eirini Mavropoulou1, Nicolae-Catalin Mechie1, Richard Knoop1, Golo Petzold1, Volker Ellenrieder1, Steffen Kunsch1, Yiannis Pilavakis2, Ahmad Amanzada1.   

Abstract

Crohn's disease (CD) and ulcerative colitis (UC) are characterized by overexpression of proinflammatory cytokines. We determined the association of serum levels of interleukin (IL)-6, soluble-IL-2-receptor (sIL-2R) and CRP as well as of faecal calprotectin (FC) values with disease activity in CD and UC patients. This prospective study included 145 CD and 84 UC patients. Serum proinflammatory biomarkers and FC levels were measured and demographic, clinical and endoscopic characteristics were collected. Uni- and multivariate statistical analyses were performed. Serum IL-6 and CRP levels as well as FC values of CD patients were associated with clinical and endoscopic remission. In multivariate analysis serum IL-6 levels remained significantly associated with clinical and endoscopic remission. FC levels were also associated with endoscopic remission in CD patients. CD patients under the threshold levels of 8.5 pg/mL and 5.5 pg/mL for serum IL-6 were in 70% and 66% in clinical and endoscopic remission, respectively. Serum sIL-2R, CRP levels and FC values of UC patients were associated in univariate analysis with clinical and endoscopic remission. In multivariate analysis CRP and FC values were associated with clinical remission and serum sIL-2R as well as FC levels with endoscopic remission. UC patients under the threshold levels of 759 IU/mL and 646 IU/mL for serum sIL-2R were in 76% and 76% in clinical and endoscopic remission, respectively. Beside CRP and FC, serum IL-6 levels in CD patients and sIL-2R levels in UC patients can be a further useful non-invasive biomarker to identify the disease activity status.

Entities:  

Year:  2020        PMID: 32470973     DOI: 10.1371/journal.pone.0233811

Source DB:  PubMed          Journal:  PLoS One        ISSN: 1932-6203            Impact factor:   3.240


  8 in total

1.  Oxidative, epigenetic changes and fermentation processes in the intestine of rats fed high-fat diets supplemented with various chromium forms.

Authors:  Wojciech Dworzański; Ewelina Cholewińska; Bartosz Fotschki; Jerzy Juśkiewicz; Katarzyna Ognik
Journal:  Sci Rep       Date:  2022-06-14       Impact factor: 4.996

2.  Targeting IL-6 by engineered Lactococcus lactis via surface-displayed affibody.

Authors:  Abida Zahirović; Aleš Berlec
Journal:  Microb Cell Fact       Date:  2022-07-16       Impact factor: 6.352

3.  Surrogate markers of mucosal healing in inflammatory bowel disease: A systematic review.

Authors:  Monica State; Lucian Negreanu; Theodor Voiosu; Andrei Voiosu; Paul Balanescu; Radu Bogdan Mateescu
Journal:  World J Gastroenterol       Date:  2021-04-28       Impact factor: 5.742

4.  Serum inflammatory markers in the diagnosis and assessment of Crohn's disease activity.

Authors:  Krystyna Słowińska-Solnica; Dorota Pawlica-Gosiewska; Katarzyna Gawlik; Danuta Owczarek; Dorota Cibor; Halina Pocztar; Tomasz Mach; Bogdan Solnica
Journal:  Arch Med Sci       Date:  2021-01-05       Impact factor: 3.318

5.  Immune marker levels in severe mental disorders: associations with polygenic risk scores of related mental phenotypes and psoriasis.

Authors:  Maren Caroline Frogner Werner; Katrine Verena Wirgenes; Alexey Shadrin; Synve Hoffart Lunding; Linn Rødevand; Gabriela Hjell; Monica Bettina Elkjær Greenwood Ormerod; Marit Haram; Ingrid Agartz; Srdjan Djurovic; Ingrid Melle; Pål Aukrust; Thor Ueland; Ole Andreas Andreassen; Nils Eiel Steen
Journal:  Transl Psychiatry       Date:  2022-01-26       Impact factor: 6.222

6.  Increased Serum Soluble Interleukin-2 Receptor Associated with Severity of Acute Exacerbation of Chronic Obstructive Pulmonary Disease.

Authors:  Yue Zhang; Lianping Ren; Jinyuan Sun; Fengfeng Han; Xuejun Guo
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2021-09-07

Review 7.  Selective Forms of Therapy in the Treatment of Inflammatory Bowel Diseases.

Authors:  Anna Kofla-Dłubacz; Katarzyna Akutko; Elżbieta Krzesiek; Tatiana Jamer; Joanna Braksator; Paula Grębska; Tomasz Pytrus; Andrzej Stawarski
Journal:  J Clin Med       Date:  2022-02-14       Impact factor: 4.241

8.  Upregulation of antimicrobial peptide expression in slc26a3-/- mice with colonic dysbiosis and barrier defect.

Authors:  Archana Kini; Bei Zhao; Marijana Basic; Urmi Roy; Aida Iljazovic; Ivan Odak; Zhenghao Ye; Brigitte Riederer; Gabriella Di Stefano; Dorothee Römermann; Christian Koenecke; André Bleich; Till Strowig; Ursula Seidler
Journal:  Gut Microbes       Date:  2022 Jan-Dec
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.